Join
Live feed
·
INSIDERFilingvia Quantisnow
Kalaris Therapeutics Inc. logo

Director Akkaraju Srinivas bought $5,000,006 worth of shares (479,847 units at $10.42) (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
KLRS· Kalaris Therapeutics Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track KLRS (Kalaris Therapeutics Inc.) and more on Quantisnow.